Ad
related to: experimental hematology biomarkers
Search results
Results From The WOW.Com Content Network
CD19 is widely expressed during all phases of B cell development until terminal differentiation into plasma cells. During B cell lymphopoiesis, CD19 surface expression starts during immunoglobulin (Ig) gene rearrangement, which coincides during B lineage commitment from hematopoietic stem cell. [8]
947 12490 Ensembl ENSG00000174059 ENSMUSG00000016494 UniProt P28906 Q64314 RefSeq (mRNA) NM_001025109 NM_001773 NM_001111059 NM_133654 RefSeq (protein) NP_001020280 NP_001764 NP_001104529 NP_598415 Location (UCSC) Chr 1: 207.88 – 207.91 Mb Chr 1: 194.62 – 194.64 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse CD34 is a transmembrane phosphoglycoprotein protein encoded by the CD34 ...
In biomedical contexts, a biomarker, or biological marker, is a measurable indicator of some biological state or condition. Biomarkers are often measured and evaluated using blood, urine, or soft tissues [1] to examine normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. [2]
Quintiles Releases Perspectives on Early Phase Oncology and Hematology Biomarkers RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- In advance of the American Society of Clinical Oncology (ASCO ...
Experimental Hematology is a peer-reviewed medical journal of hematology, which publishes original research articles and reviews, as well as the abstracts of the annual proceedings of the Society for Hematology and Stem Cells (formerly known as the International Society for Experimental Hematology).
Biomarker discovery is a medical term describing the process by which biomarkers are discovered. Many commonly used blood tests in medicine are biomarkers. There is interest in biomarker discovery on the part of the pharmaceutical industry; blood-test or other biomarkers could serve as intermediate markers of disease in clinical trials, and as possible drug targets.
In medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. It may be defined as a "cellular, biochemical or molecular alteration in cells, tissues or fluids that can be measured and evaluated to indicate normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention."
One notable biomarker garnering significant attention is the protein biomarker S100-beta in monitoring the response of malignant melanoma. In such melanomas, melanocytes , the cells that make pigment in our skin, produce the protein S100-beta in high concentrations dependent on the number of cancer cells.